The use of preoperative aspirin in cardiac surgery: A systematic review and meta‐analysis
Abstract
Background
Despite the fact that aspirin is of benefit to patients following coronary artery bypass grafting (CABG), continuation or administration of preoperative aspirin before CABG or any cardiac surgical procedure remains controversial. Therefore, we performed a systematic review and meta‐analysis to assess the influence of preoperative aspirin administration on patients undergoing cardiac surgery.
Materials and Methods
Medline database was searched using OVID SP interface. Similar searches were performed separately in EMBASE, PubMed, and Cochrane Central Registry of Controlled Trials.
Results
Twelve randomized controlled trials and 28 observational studies met our inclusion criteria and were included in the meta‐analysis. The use of preoperative aspirin in patients undergoing CABG at any dose is associated with reduced early mortality as well as a reduced incidence of postoperative acute kidney injury (AKI). Low‐dose aspirin (≤160 mg/d) is associated with a decreased incidence of perioperative myocardial infarction (MI). Administration of preoperative aspirin at any dose in patients undergoing cardiac surgery increases postoperative bleeding. Despite this effect of preoperative aspirin, it did not increase the rates of surgical re‐exploration due to excessive postoperative bleeding nor did it increase the rates of packed red blood cell transfusions (PRBC) when preoperative low‐dose aspirin (≤160 mg/d) was administered.
Conclusions
Preoperative aspirin increases the risk for postoperative bleeding. However, this did not result in an increased need for chest re‐exploration and did not increase the rates of PRBC transfusion when preoperative low‐dose (≤160 mg/d) aspirin was administered. Aspirin at any dose is associated with decreased mortality and AKI and low‐dose aspirin (≤160 mg/d) decreases the incidence of perioperative MI.